Alemtuzumab versus anti-thymocyte globulin ...
Document type :
Article dans une revue scientifique
DOI :
PMID :
Permalink :
Title :
Alemtuzumab versus anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.
Author(s) :
Robin, Marie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Raj, Kavita [Auteur]
Chevret, Sylvie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Gauthier, Jordan [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
De Lavallade, Hugues [Auteur]
Michonneau, David [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Mclornan, Donal [Auteur]
Peffault De Latour, Regis [Auteur]
Potter, Victoria [Auteur]
Kulasekararaj, Austin [Auteur]
Sicre De Fontbrune, Flore [Auteur]
Pagliuca, Antonio [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Socie, Gerard [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Mufti Ghulam, J [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Raj, Kavita [Auteur]
Chevret, Sylvie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Gauthier, Jordan [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
De Lavallade, Hugues [Auteur]
Michonneau, David [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Mclornan, Donal [Auteur]
Peffault De Latour, Regis [Auteur]
Potter, Victoria [Auteur]
Kulasekararaj, Austin [Auteur]
Sicre De Fontbrune, Flore [Auteur]
Pagliuca, Antonio [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Socie, Gerard [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Mufti Ghulam, J [Auteur]
Journal title :
European Journal of Haematology
Abbreviated title :
Eur. J. Haematol.
Volume number :
101
Pages :
466-474
Publication date :
2018-10
ISSN :
1600-0609
Keyword(s) :
unrelated transplant
graft-vs-host disease prophylaxis
anti-thymocyte globulin
alemtuzumab
myeloid disorder
graft-vs-host disease prophylaxis
anti-thymocyte globulin
alemtuzumab
myeloid disorder
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objective: Relapse and graft-vs-host disease (GVHD) are still the main complications after allogeneic hematopoietic stem cell transplantation, especially in the setting of reduced intensity regimen (RIC) and unrelated ...
Show more >Objective: Relapse and graft-vs-host disease (GVHD) are still the main complications after allogeneic hematopoietic stem cell transplantation, especially in the setting of reduced intensity regimen (RIC) and unrelated donor. We compared here anti-thymocyte globulin (ATG) or alemtuzumab as GVHD prophylaxis in patients with myeloid disease transplanted after RIC and from an unrelated donor. Method: ATG and alemtuzumab patients have been matched by age, gender, HLA matching, comorbidities and cytogenetics risk (119 patients in each group). Results: After matching, we found that ATG decreased the risk of relapse (HR: 0.55, P = .0049) and improved relapse-free survival (RFS, HR: 0.70, P = .042). The improved RFS with ATG was more pronounced in CMV-positive patients but was not influenced by disease risk. Regarding overall survival, GVHD-free relapse-free survival and transplant-related mortality, the risk was similar using ATG or alemtuzumab. Conclusion: Even if GVHD risk is lowered by alemtuzumab use, it does not translate in better outcome due to higher risk of relapse.Show less >
Show more >Objective: Relapse and graft-vs-host disease (GVHD) are still the main complications after allogeneic hematopoietic stem cell transplantation, especially in the setting of reduced intensity regimen (RIC) and unrelated donor. We compared here anti-thymocyte globulin (ATG) or alemtuzumab as GVHD prophylaxis in patients with myeloid disease transplanted after RIC and from an unrelated donor. Method: ATG and alemtuzumab patients have been matched by age, gender, HLA matching, comorbidities and cytogenetics risk (119 patients in each group). Results: After matching, we found that ATG decreased the risk of relapse (HR: 0.55, P = .0049) and improved relapse-free survival (RFS, HR: 0.70, P = .042). The improved RFS with ATG was more pronounced in CMV-positive patients but was not influenced by disease risk. Regarding overall survival, GVHD-free relapse-free survival and transplant-related mortality, the risk was similar using ATG or alemtuzumab. Conclusion: Even if GVHD risk is lowered by alemtuzumab use, it does not translate in better outcome due to higher risk of relapse.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Research team(s) :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Submission date :
2019-03-01T14:35:33Z
2023-11-29T14:39:34Z
2023-11-29T14:39:34Z